CDK4 and neoplasm: In summary, these results established that the MYC-degrading molecule A80.2HCl potentiates the therapeutic efficacy of CDK4/6i in inhibiting tumor growth, thereby providing an effective cancer treatment drug target for overcoming CDK4/6i resistance.